{"id":49547,"date":"2016-07-04T00:00:00","date_gmt":"2016-07-03T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/"},"modified":"2020-11-18T14:55:41","modified_gmt":"2020-11-18T13:55:41","slug":"avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/","title":{"rendered":"Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome"},"content":{"rendered":"<p>The clinic trial, a multicenter study, double-blind, placebo-controlled\u00a0has been designed to confirm AVX\u00a0012 Ophthalmic\u00a0Solution safety, tolerability and efficacy in DES patients, and if cleared, is expected to be\u00a0initiated in late 2016 in multiple sites across Spain.<\/p>\n<p>We believe AVX-012 has the potential to significantly improve both signs and symptoms\u00a0in this large population of DES patients, due to its selective action on\u00a0temperature\/humidity detecting neurons in the cornea and thereby regulating basal\u00a0tear\u00a0production to stabilize tear film and might contribute some analgesic effects that reduce\u00a0ocular discomfort associated with dry eye\u201d,said\u00a0Patrick Tresserras, Chief\u00a0Executive Officer of Avizorex Pharma.<\/p>\n<p>Dry Eye Syndrome\u00a0(DES)\u00a0is\u00a0a multifactorial disease of the tears and ocular surface that results in symptoms\u00a0of discomfort, visual disturbance, and tear film instability with potential damage to the\u00a0ocular surface. It is accompanied by increased\u00a0osmolality of the tear film and\u00a0inflammation of the ocular surface.\u00a0Prevalence reported in the USA, Australia and\u00a0Europe\u00a0is approximately 5-15 %, 25% in Canada and 30-50% in Asia, with the\u00a0highest prevalence being observed in subjects of Asian and Hispanic origin, and\u00a0is more common in women, especially in postmenopausal women\u00a0(Source: Gayton, 2009. EMA \/ 450332\/2012, 2012).<\/p>\n<p>&#8220;Treatment of dry eye is mainly symptomatic; very few pharmacological treatments for this disease\u00a0are currently approved in the world.\u00a0Therefore, DES\u00a0therapeutics market will grow to $4.6 Billion by 2024, being one of the fastest growing indications in ophthalmology&#8221;,\u00a0saidTresserras.<\/p>\n<p>Avizorex Pharma is a Spanish ophthalmology biotech company founded in 2013 in Alicante (Spanish autonomous community of Valencia),\u00a0with offices at Barcelona Science Park (PCB). The biotech is focused on developing novel therapies for Dry Eye Syndrome (DES) based on Prof. Carlos Belmonte\u2019s research on the role of temperature-sensitive neurons in tear film regulation\u00a0at the\u00a0<a href=\"http:\/\/in.umh.es\/origenes.aspx\" target=\"_blank\" rel=\"noopener noreferrer\">Instituto de Neurociencias de Alicante\u00a0(IN)<\/a>.\u00a0The findings of his studies were published in\u00a0Nature Medicine in 2010 (<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21076394\" target=\"_blank\" rel=\"noopener noreferrer\">doi:10.1038\/nm.2264<\/a>)\u00a0and demonstrated\u00a0that stimulation of a protein called TRMP8 activates cold receptors present on the surface of the eye and increases tear secretion naturally, hence reducing ocular dryness.\u00a0<\/p>\n<p>Avizorex closed a Series A financing round in October 2014 with Barcelona-based VC firm <a href=\"http:\/\/www.inveready.com\/en\" target=\"_blank\" rel=\"noopener noreferrer\">Inveready Technology Investment Group<\/a>. Inveready has over 70 M \u20ac under management through different funds, and has invested into Avizorex through its Life Sciences specialized fund Inveready Innvierte Biotech II.<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0\u2022\u00a0<a href=\"http:\/\/www.pcb.ub.edu\/portal\/en\/noticies\/-\/noticia\/not_avizorex-pharma-obte-la-patent-als-eua-del-seu-tractament-contra-la-sindrome-d-ull-sec?inheritRedirect=false&amp;redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_mode%3Dview%26_cercador_WAR_empleatsempresesportlet_keywords%3DAVIZOREX%26_cercador_WAR_empleatsempresesportlet_tab%3D0&amp;backURL=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_mode%3Dview%26_cercador_WAR_empleatsempresesportlet_keywords%3DAVIZOREX%26_cercador_WAR_empleatsempresesportlet_tab%3D0\" target=\"_blank\" rel=\"noopener noreferrer\">Related news [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p><a href=\"http:\/\/www.pcb.ub.edu\/portal\/en\/cerca?p_p_id=cercador_WAR_empleatsempresesportlet&amp;p_p_lifecycle=0&amp;p_p_state=maximized&amp;p_p_mode=view&amp;p_p_col_id=column-1&amp;p_p_col_count=1&amp;_cercador_WAR_empleatsempresesportlet_jspPage=%2Fhtml%2Fcommon%2Fdetall-empresa.jsp&amp;_cercador_WAR_empleatsempresesportlet_empresaId=ENT_006370&amp;_cercador_WAR_empleatsempresesportlet_redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_mode%3Dview%26_cercador_WAR_empleatsempresesportlet_keywords%3Davizorex%26_cercador_WAR_empleatsempresesportlet_tab%3D1\" target=\"_blank\" rel=\"noopener noreferrer\">Avizorex Pharma <\/a>\u2013an ophthalmology biotech\u00a0company\u00a0with offices at Barcelona Science Park (PCB)\u2013 announces the submission of a Clinical Trial Application (CTA) to the Spanish Competent Authority,\u00a0requesting clearance to initiate a Phase I\/II clinical trial investigating the use of AVX-012\u00a0Ophthalmic Solution, a small molecule with a novel mechanism of action\u00a0to treat patients suffering from mild to moderate Dry Eye Syndrome\u00a0(DES).\u00a0<\/p>\n<p>\u00a0<\/p>\n","protected":false},"author":1,"featured_media":53305,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-49547","post","type-post","status-publish","format-standard","has-post-thumbnail","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Avizorex Pharma \u2013an ophthalmology biotech\u00a0company\u00a0with offices at Barcelona Science Park (PCB)\u2013 announces the submission of a Clinical Trial Application (CTA) to the Spanish Competent Authority,\u00a0requesting clearance to initiate a Phase I\/II clinical trial investigating the use of AVX-012\u00a0Ophthalmic Solution, a small molecule with a novel mechanism of action\u00a0to treat patients suffering from mild to moderate Dry Eye Syndrome\u00a0(DES).\u00a0 \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2016-07-03T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-18T13:55:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2016\/07\/16057067375fb523f14e097.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"676\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome\",\"datePublished\":\"2016-07-03T23:00:00+00:00\",\"dateModified\":\"2020-11-18T13:55:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\\\/\"},\"wordCount\":396,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/16057067375fb523f14e097.jpeg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\\\/\",\"name\":\"Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/16057067375fb523f14e097.jpeg\",\"datePublished\":\"2016-07-03T23:00:00+00:00\",\"dateModified\":\"2020-11-18T13:55:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/16057067375fb523f14e097.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/16057067375fb523f14e097.jpeg\",\"width\":1024,\"height\":676},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/","og_locale":"en_US","og_type":"article","og_title":"Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome - Parc Cient\u00edfic de Barcelona","og_description":"Avizorex Pharma \u2013an ophthalmology biotech\u00a0company\u00a0with offices at Barcelona Science Park (PCB)\u2013 announces the submission of a Clinical Trial Application (CTA) to the Spanish Competent Authority,\u00a0requesting clearance to initiate a Phase I\/II clinical trial investigating the use of AVX-012\u00a0Ophthalmic Solution, a small molecule with a novel mechanism of action\u00a0to treat patients suffering from mild to moderate Dry Eye Syndrome\u00a0(DES).\u00a0 \u00a0","og_url":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2016-07-03T23:00:00+00:00","article_modified_time":"2020-11-18T13:55:41+00:00","og_image":[{"width":1024,"height":676,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2016\/07\/16057067375fb523f14e097.jpeg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Written by":"adminpcb","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome","datePublished":"2016-07-03T23:00:00+00:00","dateModified":"2020-11-18T13:55:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/"},"wordCount":396,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2016\/07\/16057067375fb523f14e097.jpeg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/","url":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/","name":"Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2016\/07\/16057067375fb523f14e097.jpeg","datePublished":"2016-07-03T23:00:00+00:00","dateModified":"2020-11-18T13:55:41+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2016\/07\/16057067375fb523f14e097.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2016\/07\/16057067375fb523f14e097.jpeg","width":1024,"height":676},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/avizorex-pharma-submits-clinical-trial-application-for-its-lead-compound-avx-012-for-dry-eye-syndrome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=49547"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49547\/revisions"}],"predecessor-version":[{"id":53304,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49547\/revisions\/53304"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/53305"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=49547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=49547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=49547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}